PenTAG Health Technology Assessment
PenTAG is the team of researchers within ESMI that specialise in conducting health technology assessments for national policymakers in England and Wales.
PenTAG is one of several university-based research groups in the UK contracted to produce high-quality systematic reviews and economic analyses of health technologies for NICE, the UK National Screening Committee and the NIHR Evidence Synthesis Programme.
Our work supporting NICE falls under several categories:
We produce systematic reviews of the existing literature on clinical and cost-effectiveness, critique analyses from manufacturers and develop a new economic analysis to support decisions when multiple technologies are being appraised. These projects lead to published monographs in the journal Health Technology Assessment and can also lead to journal articles.
We perform a rapid review of the evidence supporting a new drug or medical device supplied to NICE by the manufacturer. This helps to ensure that all relevant clinical effectiveness evidence is included, that cost-effectiveness analyses are robust, and that Appraisal Committees are confident that methods have been independently reviewed.
A relatively new process, similar to that for MTAs, for which we undertake an assessment of the diagnostic test accuracy, clinical outcomes and cost-effectiveness of a diagnostic technology. These projects lead to published monographs in the journal Health Technology Assessment and can also lead to journal articles.
We are participating in NICE pilots to trial new routes for appraisal aimed at differentiating the appraisal process to allow the application of light-touch, faster evaluations for simpler low-risk treatments and additional time for areas that need more detailed attention. The two pilots we have participated in so far have included the second pilot for a new, swifter, cost comparison route and the first pilot for NICE’s pathways approach which involves creation of a model for an entire treatment pathway which can be reused across multiple technology appraisals.
We produce reviews of the evidence and decision analyses for products submitted to NICE’s medical technologies guidance programme. This involves a critique of company submissions along the lines of a single technology appraisal (STA). We also provide Early Value Assessments (EVAs) of promising digital products, devices and diagnostics, reporting to NICE an overview of the current evidence and early indications of whether they are likely to prove cost-effective in the NHS. If approved by NICE, it may be used within the NHS whilst additional evidence is generated before a full reappraisal in the future.
In addition, staff members actively seek additional research funding in areas of interest to them, often stemming from work commissioned by NICE or NIHR.
Our research staff come from a variety of backgrounds, including specialists in systematic review methods, health economics, information science, computer science and statistics. We are additionally able to draw on substantial expertise from other groups in the Medical School, such as the Health Statistics and Health Economics groups.
Release of our economic models
We are happy to consider releasing copies of our economic models of health technologies to not-for-profit organisations within the UK or overseas, such as other universities or government agencies.
Our projects
| Funder | Project | Team |
|---|---|---|
|
NHS England |
Clinically meaningful minimally important differences in clinical outcomes for adults with follicular lymphoma |
C Farmer, M Muthukumar, L Trigg, D Lee, E Wilson, A Lovell |
|
NIHR James Lind Alliance PSP |
C Farmer, H Coelho, S Robinson | |
|
NICE STA |
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over |
A Lovell, A Allen, M Barnish, V Santo, D Lee |
|
NICE EVA-DAR |
Artificial intelligence software to help detect fractures on X-rays in urgent care |
C Farmer, H Coelho, S Robinson, M Muthukumar, G.J. Melendez-Torres, O Ukoumunne, E Wilson |
|
NICE STA |
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer |
A Allen, S Robinson, V Santo, A Abdelsabour, G.J. Melendez-Torres, D Lee |
|
MedTech LSA |
Compression products for venous leg ulcers: late stage assessment |
M Barnish, A Lovell, T Snowsill, D Syukriyah, G.J. Melendez-Torres, E Wilson |
|
NICE STA |
D Lee, M Barnish, A Abdelsabour, J Perks, A Lovell, G.J. Melendez-Torres | |
|
NICE STA |
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease |
A Lovell, E Wilson, A Allen, J Perks, T Douglas, C Woodrow-Hill, R Batteson, S Critchlow |
|
MedTech LSA |
C Farmer, E Wilson, M Barnish, G.J. Melendez-Torres, J Perks, A Lovell, A Abdelsabour, V Santo, D Lee | |
|
NICE HST |
Fosdenopterin for treating molybdenum cofactor deficiency type A ID6264 |
M Barnish, A Bullement, O Hale, S Robinson, J Owen, W Battershill, G.J. Melendez-Torres |
|
NICE STA |
A Lovell, J Matthews, M Barnish, E Nikram, D Lee | |
|
NICE STA |
B O'Toole, M Muthukumar, C Farmer, A Allen, A Lovell, E Wilson | |
|
NICE STA |
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over |
C Farmer, S Robinson, G.J. Melendez-Torres, H Wheat, W Sullivan, A Bullement |
|
NHS England |
Cost Effectiveness for Surgical Interventions |
C Farmer, M Muthukumar, L Trigg, Dawn L, E Wilson, A Lovell |
|
NICE STA |
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over | C Farmer, G.J. Melendez-Torres, J Matthews, L Trigg, S Robinson, A Bullement, A Hatswell |
|
NICE HST |
Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann Pick disease type B and AB) | C Farmer, B O'Toole, E Wilson, G.J. Melendez-Torres, H Coelho, N Shaw, E Nikram |
| Funder | Project | Authors | Publications |
|---|---|---|---|
| NICE PATT | Treatments for renal cell carcinoma | D Lee, G.J. Melendez-Torres, E Wilson, C Farmer, B O'Toole, M Muthukumar, L Trigg, H Coelho, A Lovell, T Snowsill, J Matthews, M Barnish, D Burns, T Nikoglou, A Brand, Z Ahmad, A Abdelsabour | |
| NICE DAR | Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis | I Tikhonova, H Yang, M Rezaei Hemami, S Bello, S Robinson, J Peters, S Dodman, A Salmon, A Kharechko, M Jani, R Haigh, T McDonald, M Pitt, M Hoyle, S Logan | Monograph |
| NIHR DAR | Lung cancer screening by low dose CT | T Snowsill, H Yang, E Griffin, L Long, J Varley-Campbell, H Coehlo, S Robinson, C Hyde | Monograph |
| NICE DAR | PartoSure (and alternative technologies identified during scoping) to help predict preterm labour in women with intact membranes | J Varley-Campbell, R Mujica-Mota, H Coehlo, C Cooper, I Tikhonova, H Yang, M Hoyle, C Hyde | Monograph |
| NICE DAR | Genetic testing for Lynch syndrome in people with colorectal cancer | H Coehlo, T Jones-Hughes, C Hyde, T Snowsill, N Huxley, C Cooper, S Briscoe | Monograph Journal (BMC Cancer) |
| NIHR HTA | Effectiveness and cost-effectiveness of conservative interventions for tendinopathy: an overview of systematic reviews of clinical effectiveness and systematic review of economic evaluations | L Long, S Briscoe, C Cooper, C Hyde, L Crathorne | Monograph |
| NICE MTA | Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer | N Huxley, L Crathorne, J Varley-Campbell, I Tikhonova, T Snowsill, S Briscoe, J Peters, M Napier, M Bond, M Hoyle |
Journal (Pharmacoeconomics) |
| NICE MTA | Everolimus, lanreotide, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression | R Mujica-Mota, J Varley-Campbell, I Tikhonova, C Cooper, E Griffin, M Haasova, J Peters, S Lucherini, J Talens-Bou, L Long, D Sherriff, M Napier, J Ramage, M Hoyle | Monograph |
| NIHR HTA | The diagnostic accuracy of hearing tests and cost-effectiveness of school entry hearing screening programmes |
H Fortnum, OC Ukoumunne, C Hyde, RS Taylor, M Ozolins, S Errington, Z Zhelev, C Pritchard, C Benton, J Moody, L Cocking, J Watson, S Roberts | Monograph |
| NIHR CLAHRC South West Peninsula (PenCLAHRC) and NIHR | Psychological consequences of false-positive screening mammograms | M Bond, R Garside, C Hyde |
Journal (BMJ Open) |
| NICE MTA | Erythropoiesis stimulating agents (epoetin and darbepoetin) for cancer-treatment induced anaemia | L Crathorne, N Huxley, M Haasova, T Snowsill, T Jones‑Hughes, M Hoyle, S Briscoe, H Coelho, L Long, A Medina‑Lara, R Mujica‑Mota, C Hyde | Monograph |
| NICE MTA | Immunosuppressive therapy for renal transplantation in adolescents and children (including a review of existing guidance 99) | M Haasova, T Snowsill, T Jones-Hughes, L Crathorne, C Cooper, J Varley-Campbell, R Mujica-Mota, H Coelho, N Huxley, J Lowe, J Dudley, S Marks, C Hyde, M Bond, R Anderson | Monograph |
| NICE MTA | Immunosuppressive therapy for renal transplantation in adults (including a review of existing guidance 85) | T Jones-Hughes, T Snowsill, M Haasova, H Coelho, L Crathorne, C Cooper, R Mujica-Mota, J Peters, J Varley-Campbell, N Huxley, J Moore, M Allwood, J Lowe, C Hyde, M Hoyle, M Bond, R Anderson |
Journal (Nephrology Dialysis Transplantation) |
| NICE DA | Sysmex RD-100i OSNA system and Metasin for intraoperative detection of sentinel lymph node metastases in breast cancer | N Huxley, T Jones‑Hughes, H Coelho, T Snowsill, C Cooper, K Cooper, Y Meng, C Hyde, R Mujica‑Mota | Monograph |
| NIHR HTA | Diagnostic strategies for identifying Lynch syndrome in early-onset colorectal cancer patients | T Snowsill, N Huxley, M Hoyle, T Jones‑Hughes, H Coelho, C Cooper, I Frayling, C Hyde |
Journal article (BMC Cancer) |
| NICE MTA | Bevacizumab, Cetuximab, and Panitumumab for in colorectal cancer (metastatic) after failure of 1st line chemotherapy | M Hoyle, L Crathorne, J Peters, T Jones‑Hughes, C Cooper, M Napier, P Tappenden, C Hyde |
Journal article (Value in Health) |
| NIHR HTA | Psychological consequences of false positive mammograms | M Bond, T Pavey, K Welch, C Cooper, R Garside, S Dean, C Hyde | Journal article (Editor's choice, Evidence Based Medicine) |
| NICE MTA | Dasatinib and Nilotinib for the 1st line treatment of chronic phase CML | T Pavey, M Hoyle, O Ciani, L Crathorne, T Jones‑Hughes, C Cooper, L Osipenko, M Venkatachalam, C Rudin, O Ukoumunne, R Garside, R Anderson | |
| NICE MTA | Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant or imatinib-intolerant CML | G Rogers, M Hoyle, J Thompson Coon, T Moxham, Z Liu, M Pitt, K Stein | Monograph Journal article (Value in Health) |
| NICE MTA | Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | M Bond, G Rogers, J Peters, R Anderson, M Hoyle, A Miners, T Moxham, S Davis, P Thokala, A Wailoo, M Jeffreys, C Hyde | Journal article #1 (International Journal of Technology Assessment in Health Care) Journal article #2 (Age and Ageing) |
| NIHR HTA | Computerised decision support systems in Order Communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems | C Main, T Moxham, JC Wyatt, J Kay, R Anderson, K Stein | Monograph |
| NICE MTA | Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: A systematic review and economic model | J Thompson Coon, M Hoyle, C Green, Z Liu, K Welch, T Moxham, K Stein | Journal article #1 (Value in Health) Journal article #2 (Value in Health) Journal article #3 (British Journal of Cancer) |
| NIHR HTA | Weight management schemes for the under fives | M Bond, K Wyatt, J Lloyd, K Welch, R Taylor | |
| NICE MTA | Cochlear implants for severe to profound deafness in children and adults | M Bond, S Mealing, R Anderson, J Elston, G Weiner, R Taylor, M Hoyle, Z Liu, A Price, K Stein | Journal article #1 (Clinical Otolaryngology) Journal article #2 (updated searches; Clinical Otolaryngology) |
| NICE MTA | Methods of storing donated kidneys from deceased donors | M Bond, M Pitt, J Akoh, T Moxham, M Hoyle, R Anderson | |
| NIHR HTA | Systematic review of the harmful health effects of taking ecstasy (MDMA) for recreational purposes | G Rogers, J Elston, R Garside, C Roome, R Taylor, P Younger, A Zawada, M Somerville | |
| NIHR HTA | C Main, Z Liu, K Welch, G Weiner, SQ Jones, K Stein |
|
Our Consultancy
PenTAG Consulting offers research, training and advice to the pharmaceutical and medical devices industries, the NHS and other organisations worldwide.
Our Staff
